FindMyKOL
Clinical trialNCT00421252TerminatedPhase 4Interventional

Role of Plavix in Hemorrhagic and Ischemic Complications of Catheterization.

NCT00421252 is a phase 4 interventional trial sponsored by Beth Israel Deaconess Medical Center. As of 21 Nov 2026, it was terminated. It studies Clopidogrel in Bleeding, Coronary Artery Disease and 1 more condition. The registry lists an enrollment of 18 participants at 1 site in 1 country. The registry lists a start date of 31 Jan 2007 and a primary completion date of 30 Nov 2007.

SponsorBeth Israel Deaconess Medical Center →Enrollment18BleedingCoronary Artery DiseaseMyocardial Ischemia
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT00421252
FieldValue
Registry IDNCT00421252
StatusTerminated
PhasePhase 4
Study typeInterventional trial
Lead sponsorBeth Israel Deaconess Medical Center
Enrollment18
Registered sites1
Countries1
ConditionsBleeding, Coronary Artery Disease and Myocardial Ischemia
DrugsClopidogrel
Start31 Jan 2007
Primary completion30 Nov 2007
Study completion31 Jan 2008
Last update posted14 Apr 2017

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Patients who have stents placed in their coronary arteries require treatment with at least two medications to prevent platelets from sticking to the stainless steel stent and forming a blood clot that can result in a heart attack. The 2 anti-platelet medications used for most patients with stents are aspirin and clopidogrel (Plavix). These are usually prescribed for 1-12 months (the length of time depends on the number and types of stents implanted). Although the typical long-term dose of clopidogrel is 75 mg by mouth once daily, a larger dose (known as a loading dose) is usually given at the start of treatment to help the medication take effect more quickly. Prior to January 2006, most patients at the Beth Israel Deaconess Medical Center (BIDMC) who were undergoing PCI and who had not already been taking clopidogrel would receive a loading dose of 300-600 mg of clopidogrel in the cardiac catheterization procedure room immediately after the angioplasty and stenting portion of the procedure. However, several recent studies suggest that administering clopidogrel 600 mg at least two hours prior to an angioplasty procedure can reduce the rate of complications afterwards (especially reducing the chances of detectable damage to the heart muscle). The main purpose of this study is to see whether giving a loading dose of clopidogrel 600 mg to outpatients scheduled to undergo cardiac catheterization with coronary angiography can decrease the risk of procedure-related complications during the 14 days following the cardiac catheterization compared to a strategy of giving clopidogrel 600 mg after the procedure only to those who undergo angioplasty. We will focus our attention particularly on detecting damage to heart muscle following angioplasty (which might be expected to improve with a loading dose of clopidogrel before the procedure) and on bleeding and other groin complications (which might worsen with clopidogrel loading before the procedure). The drug clopidogrel has been approved by the Food and Drug Administration (FDA) for use in patients with a recent or ongoing heart attack, narrowings in major blood vessels outside the heart, or recent stroke with a loading dose of 300 mg followed by 75 mg once daily. It has been used in several large studies with a loading dose of 600 mg without a significant increase in major adverse effects. However, we do not yet know if it is useful or safe when given as a loading dose of 600 mg before cardiac catheterization for outpatients with stable symptoms and who are not thought to be in the midst of a heart attack.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Massachusetts, United States1 site
  • Beth Israel Deaconess Medical Center

    Boston

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusetts: 1 siteMA1Rhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT00421252

Each answer restates registry values shown on this page.

What is NCT00421252?

NCT00421252 is a phase 4 interventional trial sponsored by Beth Israel Deaconess Medical Center. It studies Clopidogrel in Bleeding, Coronary Artery Disease and 1 more condition.

Who leads NCT00421252?

The registry names Joseph P Carrozza, MD (principal investigator, Beth Israel Deaconess Medical Center) as the overall official.

Where does NCT00421252 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT00421252 study?

The registered drug and biological interventions are Clopidogrel.

When did NCT00421252 end?

The registry lists a primary completion date of 30 Nov 2007 and a study completion date of 31 Jan 2008. The sponsor last updated the record on 14 Apr 2017.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.